Clinical Trials
Page 2 • 12 itemsAccess global clinical trial data, regulatory updates, and competitive intelligence for strategic pharma R&D and investment decisions.
Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Era
Purdue Pharma, the manufacturer of OxyContin, is ceasing operations as part of a $7.4 billion settlement to resolve claims related to the opioid crisis. This landmark deal signifies a major turning point in the legal and societal reckoning with the epidemic.
Verified Clinical Trials Partners with Chubb to Enhance Patient Safety and Data Quality in Clinical Research
Verified Clinical Trials and Chubb announce strategic alliance to improve clinical trial participant safety, data quality, and study integrity worldwide.
Huahui Health Partners with BeOne Medicines for HH160 Trispecific Antibody in Global Oncology Deal
Huahui Health grants BeOne Medicines exclusive worldwide rights to develop HH160, a novel trispecific antibody for cancer immunotherapy treatment.
Prolacta's Human Milk-Based Fortifiers Receive World's First Prescription Drug Status in Japan Following JASMINE Trial Success
Prolacta achieves global regulatory milestone as Japan grants prescription drug status to human milk-based fortifiers for premature infants based on JASMINE trial data.
Axoft Raises $55M Series A to Advance Brain-Computer Interface Clinical Trials Globally
Axoft secures $55M Series A funding led by C.P. Group Innovation to advance bio-inspired brain-computer interface technology into global clinical trials.
Taimei Technology Debuts AI-Powered Clinical Trial Platform at BioKorea 2026
Taimei Technology showcases AI-driven drug development platform at BioKorea 2026, planning Korea market entry with advanced clinical research solutions.
Energenesis Biomedical ENERGI-F703DFU Diabetic Foot Ulcer Treatment Data to Be Presented at EWMA 2026
Energenesis Biomedical will present clinical data for ENERGI-F703DFU gel, a novel topical treatment for diabetic foot ulcers, at EWMA 2026 in Bremen.
Ascletis Pharma to Present Diabetes Drug Data at American Diabetes Association 2026 Scientific Sessions
Ascletis Pharma will present clinical data on multiple diabetes programs at the ADA 2026 Scientific Sessions, showcasing pipeline developments in diabetes treatment.
TLX597-Tx PSMA Radioligand Therapy Shows Promise in OPTIMAL-PSMA Trial for Early-Stage Prostate Cancer
TLX597-Tx radioligand therapy demonstrates low organ toxicity in OPTIMAL-PSMA trial, potentially enabling dose intensification for prostate cancer treatment.
PMDA SAKIGAKE Designation: Accelerating Innovative Therapies in Japan
The PMDA SAKIGAKE Designation fast-tracks innovative therapies, such as XYZ Drug for cancer, enhancing patient access to groundbreaking treatments in Japan.
Insilico Medicine's Rentosertib Inhalation Solution Receives IND Clearance for First AI-Driven Direct-to-Lung Clinical Trial
Insilico Medicine's AI-discovered Rentosertib inhalation solution gets IND clearance for direct-to-lung delivery, marking a milestone in AI drug development.
Soleno Therapeutics Faces Securities Fraud Lawsuit Over Alleged Sham Phase 3 Clinical Trials
Soleno Therapeutics hit with securities fraud allegations claiming company conducted fraudulent Phase 3 trials that led to FDA drug approval.